These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32740471)

  • 1. Defining and Identifying Per-protocol Effects in Randomized Trials.
    Rudolph JE; Naimi AI; Westreich DJ; Kennedy EH; Schisterman EF
    Epidemiology; 2020 Sep; 31(5):692-694. PubMed ID: 32740471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifiability and estimation of causal effects in randomized trials with noncompliance and completely nonignorable missing data.
    Chen H; Geng Z; Zhou XH
    Biometrics; 2009 Sep; 65(3):675-82. PubMed ID: 18759847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causal inference methods to assess safety upper bounds in randomized trials with noncompliance.
    Wang Y; Berlin JA; Pinheiro J; Wilcox MA
    Clin Trials; 2015 Jun; 12(3):265-75. PubMed ID: 25733675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating causal effects of treatment in RCTs with provider and subject noncompliance.
    Sheng E; Li W; Zhou XH
    Stat Med; 2019 Feb; 38(5):738-750. PubMed ID: 30347462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency and robustness of causal effect estimators when noncompliance is measured with error.
    Boatman JA; Vock DM; Koopmeiners JS
    Stat Med; 2018 Dec; 37(28):4126-4141. PubMed ID: 30109713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An introduction to spillover effects in cluster randomized trials with noncompliance.
    Keele L; Kang H
    Clin Trials; 2022 Aug; 19(4):375-379. PubMed ID: 35510562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dichotomizing partial compliance and increased participant burden in factorial designs: the performance of four noncompliance methods.
    Merrill PD; McClure LA
    Trials; 2015 Nov; 16():523. PubMed ID: 26573840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating causal effects from a randomized clinical trial when noncompliance is measured with error.
    Boatman JA; Vock DM; Koopmeiners JS; Donny EC
    Biostatistics; 2018 Jan; 19(1):103-118. PubMed ID: 28605411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of methods for estimating the causal effect of a treatment in randomized clinical trials subject to noncompliance.
    Little RJ; Long Q; Lin X
    Biometrics; 2009 Jun; 65(2):640-9. PubMed ID: 18510650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the Effect of a Treatment When There Is Nonadherence in a Trial.
    Richardson DB; Dukes O; Tchetgen Tchetgen EJ
    Am J Epidemiol; 2023 Oct; 192(10):1772-1780. PubMed ID: 37338999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discussion of "Identifiability and estimation of causal effects in randomized trials with noncompliance and completely nonignorable missing data".
    Small DS; Cheng J
    Biometrics; 2009 Sep; 65(3):682-6; discussion 689-91. PubMed ID: 18759846
    [No Abstract]   [Full Text] [Related]  

  • 15. Multiple imputation methods for treatment noncompliance and nonresponse in randomized clinical trials.
    Taylor L; Zhou XH
    Biometrics; 2009 Mar; 65(1):88-95. PubMed ID: 18397338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interval-cohort designs and bias in the estimation of per-protocol effects: a simulation study.
    Young JG; Vatsa R; Murray EJ; Hernán MA
    Trials; 2019 Sep; 20(1):552. PubMed ID: 31488202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrasting approaches for addressing non-adherence in randomized controlled trials: An illustration from the REFLUX trial.
    Keele L; Grieve R
    Clin Trials; 2022 Feb; 19(1):97-106. PubMed ID: 34949104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Joint modeling compliance and outcome for causal analysis in longitudinal studies.
    Gao X; Brown GK; Elliott MR
    Stat Med; 2014 Sep; 33(20):3453-65. PubMed ID: 23576159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the causal effect of randomization versus treatment preference in a doubly randomized preference trial.
    Marcus SM; Stuart EA; Wang P; Shadish WR; Steiner PM
    Psychol Methods; 2012 Jun; 17(2):244-54. PubMed ID: 22563844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation.
    Greenland S; Lanes S; Jara M
    Clin Trials; 2008; 5(1):5-13. PubMed ID: 18283074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.